IBDEI0Z4 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16503,1,3,0)
 ;;=3^Malig Neop Rectum
 ;;^UTILITY(U,$J,358.3,16503,1,4,0)
 ;;=4^C20.
 ;;^UTILITY(U,$J,358.3,16503,2)
 ;;=^267090
 ;;^UTILITY(U,$J,358.3,16504,0)
 ;;=C43.9^^67^759^5
 ;;^UTILITY(U,$J,358.3,16504,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16504,1,3,0)
 ;;=3^Malig Melanoma Skin,Unspec
 ;;^UTILITY(U,$J,358.3,16504,1,4,0)
 ;;=4^C43.9
 ;;^UTILITY(U,$J,358.3,16504,2)
 ;;=^5001015
 ;;^UTILITY(U,$J,358.3,16505,0)
 ;;=C22.9^^67^759^20
 ;;^UTILITY(U,$J,358.3,16505,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16505,1,3,0)
 ;;=3^Malig Neop Liver,Unspec as Prim/Second
 ;;^UTILITY(U,$J,358.3,16505,1,4,0)
 ;;=4^C22.9
 ;;^UTILITY(U,$J,358.3,16505,2)
 ;;=^267096
 ;;^UTILITY(U,$J,358.3,16506,0)
 ;;=C32.9^^67^759^18
 ;;^UTILITY(U,$J,358.3,16506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16506,1,3,0)
 ;;=3^Malig Neop Larynx,Unspec
 ;;^UTILITY(U,$J,358.3,16506,1,4,0)
 ;;=4^C32.9
 ;;^UTILITY(U,$J,358.3,16506,2)
 ;;=^5000956
 ;;^UTILITY(U,$J,358.3,16507,0)
 ;;=C50.911^^67^759^10
 ;;^UTILITY(U,$J,358.3,16507,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16507,1,3,0)
 ;;=3^Malig Neop Breast,Right,Female
 ;;^UTILITY(U,$J,358.3,16507,1,4,0)
 ;;=4^C50.911
 ;;^UTILITY(U,$J,358.3,16507,2)
 ;;=^5001195
 ;;^UTILITY(U,$J,358.3,16508,0)
 ;;=C50.912^^67^759^9
 ;;^UTILITY(U,$J,358.3,16508,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16508,1,3,0)
 ;;=3^Malig Neop Breast,Left,Female
 ;;^UTILITY(U,$J,358.3,16508,1,4,0)
 ;;=4^C50.912
 ;;^UTILITY(U,$J,358.3,16508,2)
 ;;=^5001196
 ;;^UTILITY(U,$J,358.3,16509,0)
 ;;=C24.9^^67^759^6
 ;;^UTILITY(U,$J,358.3,16509,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16509,1,3,0)
 ;;=3^Malig Neop Biliary Tract,Unspec
 ;;^UTILITY(U,$J,358.3,16509,1,4,0)
 ;;=4^C24.9
 ;;^UTILITY(U,$J,358.3,16509,2)
 ;;=^5000942
 ;;^UTILITY(U,$J,358.3,16510,0)
 ;;=C90.00^^67^759^24
 ;;^UTILITY(U,$J,358.3,16510,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16510,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,16510,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,16510,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,16511,0)
 ;;=C85.89^^67^759^29
 ;;^UTILITY(U,$J,358.3,16511,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16511,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma NEC,Extranodal & Solid Organ
 ;;^UTILITY(U,$J,358.3,16511,1,4,0)
 ;;=4^C85.89
 ;;^UTILITY(U,$J,358.3,16511,2)
 ;;=^5001730
 ;;^UTILITY(U,$J,358.3,16512,0)
 ;;=C79.51^^67^759^32
 ;;^UTILITY(U,$J,358.3,16512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16512,1,3,0)
 ;;=3^Secondary Malig Neop Bone
 ;;^UTILITY(U,$J,358.3,16512,1,4,0)
 ;;=4^C79.51
 ;;^UTILITY(U,$J,358.3,16512,2)
 ;;=^5001350
 ;;^UTILITY(U,$J,358.3,16513,0)
 ;;=C79.52^^67^759^31
 ;;^UTILITY(U,$J,358.3,16513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16513,1,3,0)
 ;;=3^Secondary Malig Neop  Bone Marrow
 ;;^UTILITY(U,$J,358.3,16513,1,4,0)
 ;;=4^C79.52
 ;;^UTILITY(U,$J,358.3,16513,2)
 ;;=^5001351
 ;;^UTILITY(U,$J,358.3,16514,0)
 ;;=C92.00^^67^759^25
 ;;^UTILITY(U,$J,358.3,16514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16514,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16514,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,16514,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,16515,0)
 ;;=C92.40^^67^759^30
 ;;^UTILITY(U,$J,358.3,16515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16515,1,3,0)
 ;;=3^Promyelocytic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16515,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,16515,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,16516,0)
 ;;=C92.50^^67^759^27
 ;;^UTILITY(U,$J,358.3,16516,1,0)
 ;;=^358.31IA^4^2
